[Prospects for use of short peptides in pharmacotherapeutic correction of Alzheimer's disease.].

Advances in gerontology = Uspekhi gerontologii2024PMID: 38944767

Plain Language Summary

This review examines how a group of short peptides, including Lys-Glu, Glu-Asp-Arg, and Met-Glu-His-Phe-Pro-Gly-Pro, act on multiple targets relevant to Alzheimer's disease rather than attacking a single pathway. The authors argue that this multi-target profile makes them better suited to treating a complex disease like Alzheimer's than single-target drugs. The peptides are proposed as candidates for further development alongside or in contrast to conventional therapeutic strategies.

Abstract

Alzheimer's disease (AD) is the most common neurodegenerative disorder, characterized by progressive cognitive decline. This review discusses current therapeutic strategies for the treatment of Alzheimer's disease, their limitations, and potential prospects. The feasibility of comprehensive approach for AD therapy is considered in contrast to the classical method in the development of therapeutic strategy. Leu-Ile, Glu-Trp, Lys-Glu, Gly-Pro, Glu-Asp-Arg, Lys-Glu-Asp, Met-Glu-His-Phe-Pro-Gly-Pro short peptides are described as multitarget agents with a wide range of activity.

Authors

Ilina, A R; Popovich, I G; Ryzhak, G A; Khavinson, V K

Keywords

Alzheimer's diseasedementianeuroprotectionpeptides